Albert Lowe
Stock Analyst at Craig-Hallum
(3.30)
# 1,021
Out of 5,157 analysts
10
Total ratings
40%
Success rate
42.48%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Albert Lowe
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Initiates: Buy | $175 | $139.69 | +25.28% | 1 | Dec 4, 2025 | |
| NGNE Neurogene | Initiates: Buy | $50 | $23.03 | +117.11% | 1 | Jun 17, 2025 | |
| ATOS Atossa Therapeutics | Initiates: Buy | $20 | $4.78 | +318.41% | 1 | Jun 5, 2025 | |
| IRD Opus Genetics | Initiates: Buy | $6 | $5.01 | +19.76% | 1 | Apr 11, 2025 | |
| SKYE Skye Bioscience | Maintains: Buy | $18 → $14 | $0.72 | +1,840.94% | 2 | Mar 21, 2025 | |
| SABS SAB Biotherapeutics | Initiates: Buy | $11 | $4.58 | +140.17% | 1 | Oct 9, 2024 | |
| CRDF Cardiff Oncology | Initiates: Buy | $8 | $2.01 | +298.01% | 1 | Sep 6, 2024 | |
| LCTX Lineage Cell Therapeutics | Initiates: Buy | $4 | $1.68 | +138.10% | 1 | Aug 20, 2024 | |
| PMVP PMV Pharmaceuticals | Initiates: Buy | $6 | $1.60 | +275.00% | 1 | May 13, 2024 |
Palvella Therapeutics
Dec 4, 2025
Initiates: Buy
Price Target: $175
Current: $139.69
Upside: +25.28%
Neurogene
Jun 17, 2025
Initiates: Buy
Price Target: $50
Current: $23.03
Upside: +117.11%
Atossa Therapeutics
Jun 5, 2025
Initiates: Buy
Price Target: $20
Current: $4.78
Upside: +318.41%
Opus Genetics
Apr 11, 2025
Initiates: Buy
Price Target: $6
Current: $5.01
Upside: +19.76%
Skye Bioscience
Mar 21, 2025
Maintains: Buy
Price Target: $18 → $14
Current: $0.72
Upside: +1,840.94%
SAB Biotherapeutics
Oct 9, 2024
Initiates: Buy
Price Target: $11
Current: $4.58
Upside: +140.17%
Cardiff Oncology
Sep 6, 2024
Initiates: Buy
Price Target: $8
Current: $2.01
Upside: +298.01%
Lineage Cell Therapeutics
Aug 20, 2024
Initiates: Buy
Price Target: $4
Current: $1.68
Upside: +138.10%
PMV Pharmaceuticals
May 13, 2024
Initiates: Buy
Price Target: $6
Current: $1.60
Upside: +275.00%